Rexlemestrocel-L is under clinical development by Mesoblast and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Rexlemestrocel-L’s likelihood of approval (LoA) and phase transition for Chronic Heart Failure took place on 18 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Rexlemestrocel-L Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Rexlemestrocel-L is under development for the treatment of acute myocardial infarction, end-stage hypoplastic left heart syndrome, advanced (class II-IV) chronic congestive heart failure due to left ventricular dysfunction and end-stage ischemic heart failure. It is administered as intra-myocardial (intra-cardiac) injection. The therapeutic candidate is based on mesenchymal precursor cell (MPC) technology platform.
Mesoblast is a regenerative medicine company that develops regenerative cell-based products. Its most advanced candidate remestemcel-L is in phase III trials under the brand name RYONCIL for the treatment of pediatric steroid-refractory acute graft versus host disease (SR-aGVHD). Mesoblast is advancing rexlemestrocel for localized inflammatory diseases including advanced heart failure, end-stage ischemic heart failure, and MPc-06-ID (rexlemestrocel) for the treatment of chronic low back pain. The company employs its proprietary technology platform, mesenchymal lineage adult stem cells (MLCs), to discover and treat cardiac diseases, and hematological diseases, spine and musculoskeletal disorders and immune-mediated and inflammatory conditions. The company has operations in the US, Australia, and Singapore. Mesoblast is headquartered in Melbourne, Victoria, Australia.
Quick View Rexlemestrocel-L LOA Data
|Highest Development Stage|